Top

Current Fungal Infection Reports

Published in:

01-09-2021 | Voriconazole | Fungal Infections in Transplantation (S Shoham, Section Editor)

Scedosporium and Lomentospora infections in lung transplant recipients

Authors: Blandine Rammaert, Zoe C. F. Neoh, Sharon C-A. Chen, David C. M. Kong, Monica A. Slavin

Published in: Current Fungal Infection Reports | Issue 3/2021

Abstract

Purpose of Review

Infections caused by uncommon or rare mould pathogens often complicate the management of lung transplant (Tx) recipients contributing to high mortality. This review explores the epidemiology, diagnosis, and management of Scedosporium and Lomentospora (S/L) infections in lung Tx recipients as well as highlighting constraints in the current management and areas for future research.

Recent Findings

The number of reported S/L infections remains low among lung Tx recipients whilst the diagnosis and treatment of S/L infections remains challenging. The very few studies which evaluated clinical characteristics, prognostic factors and treatment outcomes of lung Tx patients with lomentosporiosis and/or scedosporiosis were limited by single-centre and observational study design.

Summary

The requirement to standardise surveillance and culture procedure for S/L infections in lung Tx remains. Better diagnostic tools and antifungal agents are needed to manage S/L infection in this patient cohort. Prospective clinical registries or online databases for lung Tx recipients with these rare mould infections are essential to refine disease management and to improve clinical outcomes in the future.

ISHLT: The International Society for Heart & Lung Transplantation - / [Internet]. [cited 2019 Dec 30]. Available from: https://ishltregistries.org/registries/slides.asp

Doligalski CT, Benedict K, Cleveland AA, Park B, Derado G, Pappas PG, et al. Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant. 2014;14(6):1328–33. https://doi.org/10.1111/ajt.12691.CrossRefPubMedPubMedCentral

Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, Olyaei A, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010;12(3):220–9. https://doi.org/10.1111/j.1399-3062.2010.00492.x.CrossRefPubMed

Bouchara J-P, Le Govic Y, Kabbara S, Cimon B, Zouhair R, Hamze M, et al. Advances in understanding and managing Scedosporium respiratory infections in patients with cystic fibrosis. Expert Rev Respir Med. 2019;14:1–15. https://doi.org/10.1080/17476348.2020.1705787.CrossRef

Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis. 2006;8(4):213–8. https://doi.org/10.1111/j.1399-3062.2006.00156.x.CrossRefPubMed

Lackner M, de Hoog GS, Yang L, Ferreira Moreno L, Ahmed SA, Andreas F, et al. Proposed nomenclature for Pseudallescheria, Scedosporium and related genera. Fungal Diversity. 2014;67(1):1–10. https://doi.org/10.1007/s13225-014-0295-4.CrossRef

Harun A, Gilgado F, Chen SCA, Meyer W. Abundance of Pseudallescheria/Scedosporium species in the Australian urban environment suggests a possible source for scedosporiosis including the colonization of airways in cystic fibrosis. Med Mycol. 2010;48(Suppl 1):S70–6. https://doi.org/10.3109/13693786.2010.515254.CrossRefPubMed

Harun A, Serena C, Gilgado F, Chen SCA, Meyer W. Scedosporium aurantiacum is as virulent as S. prolificans, and shows strain-specific virulence differences, in a mouse model. Med Mycol. 2010;48(Suppl 1):S45-51. https://doi.org/10.3109/13693786.2010.517224.CrossRefPubMed

Kaltseis J, Rainer J, De Hoog GS. Ecology of Pseudallescheria and Scedosporium species in human-dominated and natural environments and their distribution in clinical samples. Med Mycol. 2009;47(4):398–405. https://doi.org/10.1080/13693780802585317.CrossRefPubMed

10.

Rougeron A, Schuliar G, Leto J, Sitterlé E, Landry D, Bougnoux M-E, et al. Human-impacted areas of France are environmental reservoirs of the Pseudallescheria boydii / Scedosporium apiospermum species complex. Environ Microbiol. 2014;17:1039–48. https://doi.org/10.1111/1462-2920.12472.CrossRefPubMed

11.

Ramirez-Garcia A, Pellon A, Rementeria A, Buldain I, Barreto-Bergter E, Rollin-Pinheiro R, et al. Scedosporium and Lomentospora: an updated overview of underrated opportunists. Med Mycol. 2018;56(suppl_1):102–25. https://doi.org/10.1093/mmy/myx113.CrossRefPubMed

12.

Husain S, Sole A, Alexander BD, Aslam S, Avery R, Benden C, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. J Heart Lung Transplant. 2016;35(3):261–82. https://doi.org/10.1016/j.healun.2016.01.007.CrossRefPubMed

13.

Vadnerkar A, Clancy CJ, Celik U, Yousem SA, Mitsani D, Toyoda Y, et al. Impact of mold infections in explanted lungs on outcomes of lung transplantation. Transplantation. 2010;89(2):253–60. https://doi.org/10.1097/TP.0b013e3181c3c417.CrossRefPubMedPubMedCentral

14.

Cimon B, Carrère J, Vinatier JF, Chazalette JP, Chabasse D, Bouchara JP. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2000;19(1):53–6.CrossRef

15.

Masoud-Landgraf L, Badura A, Eber E, Feierl G, Marth E, Buzina W. Modified culture method detects a high diversity of fungal species in cystic fibrosis patients. Med Mycol. 2014:52(2)179–86. https://doi.org/10.3109/13693786.2013.792438.

16.

Parize P, Billaud S, Bienvenu AL, Bourdy S, le Pogam MA, Reix P, et al. Impact of Scedosporium apiospermum complex seroprevalence in patients with cystic fibrosis. J Cyst Fibros. 2014;13:667–73. https://doi.org/10.1016/j.jcf.2014.01.011.CrossRefPubMed

17.

Ziesing S, Suerbaum S, Sedlacek L. Fungal epidemiology and diversity in cystic fibrosis patients over a 5-year period in a national reference center. Med Mycol. 2016;54(8):781–6. https://doi.org/10.1093/mmy/myw035.CrossRefPubMed

18.

Blyth CC, Harun A, Middleton PG, Sleiman S, Lee O, Sorrell TC, et al. Detection of occult Scedosporium species in respiratory tract specimens from patients with cystic fibrosis by use of selective media. J Clin Microbiol. 2010;48(1):314–6. https://doi.org/10.1128/JCM.01470-09.CrossRefPubMed

19.

Horré R, Marklein G, Siekmeier R, Nidermajer S, Reiffert SM. Selective isolation of Pseudallescheria and Scedosporium species from respiratory tract specimens of cystic fibrosis patients. Respiration. 2009;77(3):320–4. https://doi.org/10.1159/000167419.CrossRefPubMed

20.

Paugam A, Baixench M-T, Demazes-Dufeu N, Burgel P-R, Sauter E, Kanaan R, et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol. 2010;48(Suppl 1):S32–6. https://doi.org/10.3109/13693786.2010.503665.CrossRefPubMed

21.

Hong G, Lechtzin N, Hadjiliadis D, Kawut SM. Inhaled antibiotic use is associated with Scedosporium/Lomentospora species isolation in cystic fibrosis. Pediatr Pulmonol. 2019;54(2):133–40. https://doi.org/10.1002/ppul.24210.CrossRefPubMed

22.

Sedlacek L, Graf B, Schwarz C, Albert F, Peter S, Würstl B, et al. Prevalence of Scedosporium species and Lomentospora prolificans in patients with cystic fibrosis in a multicenter trial by use of a selective medium. J Cyst Fibros. 2015;14(2):237–41. https://doi.org/10.1016/j.jcf.2014.12.014.CrossRefPubMed

23.

Williamson EC, Speers D, Arthur IH, Harnett G, Ryan G, Inglis TJ. Molecular epidemiology of Scedosporium apiospermum infection determined by PCR amplification of ribosomal intergenic spacer sequences in patients with chronic lung disease. J Clin Microbiol. 2001;39(1):47–50. https://doi.org/10.1128/JCM.39.1.47-50.2001.CrossRefPubMedPubMedCentral

24.

Bernhardt A, Sedlacek L, Wagner S, Schwarz C, Würstl B, Tintelnot K. Multilocus sequence typing of Scedosporium apiospermum and Pseudallescheria boydii isolates from cystic fibrosis patients. J Cyst Fibros. 2013;12(6):592–8. https://doi.org/10.1016/j.jcf.2013.05.007.CrossRefPubMed

25.

Defontaine A, Zouhair R, Cimon B, Carrère J, Bailly E, Symoens F, et al. Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol. 2002;40(6):2108–14.CrossRef

26.

Schwarz C, Brandt C, Antweiler E, Krannich A, Staab D, Schmitt-Grohé S, et al. Prospective multicenter German study on pulmonary colonization with Scedosporium /Lomentospora species in cystic fibrosis: Epidemiology and new association factors. PLoS ONE. 2017;12(2):e0171485. https://doi.org/10.1371/journal.pone.0171485.CrossRefPubMedPubMedCentral

27.

Chang A, Musk M, Lavender M, Wrobel J, Yaw MC, Lawrence S, et al. Epidemiology of invasive fungal infections in lung transplant recipients in Western Australia. Transpl Infect Dis. 2019;21(3):e13085. https://doi.org/10.1111/tid.13085.CrossRefPubMed

28.

Parize P, Boussaud V, Poinsignon V, Sitterle E, Botterel F, Lefeuvre S, et al. Clinical outcome of cystic fibrosis patients colonized by Scedosporium species following lung transplantation: A single-center 15-year experience. Transpl Infect Dis. 2017;19(15):e12738. https://doi.org/10.1111/tid.12738.

29.

Johnson LS, Shields RK, Clancy CJ. Epidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipients. Transpl Infect Dis. 2014;16(4):578–87. https://doi.org/10.1111/tid.12244.CrossRefPubMed

30.••

Rammaert B, Puyade M, Cornely OA, Seidel D, Grossi P, Husain S, et al. Perspectives on Scedosporium species and Lomentospora prolificans in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology. Transpl Infect Dis. 2019;21(5):e13141. https://doi.org/10.1111/tid.13141An international survey describing the current clinical practice on management of S/L colonisation and infection of lower respiratory tract in lung transplant centres.CrossRefPubMed

31.

Tamm M, Malouf M, Glanville A. Pulmonary scedosporium infection following lung transplantation. Transpl Infect Dis. 2001;3(4):189–94. https://doi.org/10.1034/j.1399-3062.2001.30402.x.CrossRefPubMed

32.

Heath CH, Slavin MA, Sorrell TC, Handke R, Harun A, Phillips M, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect. 2009;15(7):689–93. https://doi.org/10.1111/j.1469-0691.2009.02802.x.CrossRefPubMed

33.

Brunet K, Alanio A, Lortholary O, Rammaert B. Reactivation of dormant/latent fungal infection. J Infect. 2018;77(6):463–8. https://doi.org/10.1016/j.jinf.2018.06.016.CrossRefPubMed

34.

Silveira FP, Kwak EJ, Paterson DL, Pilewski JM, McCurry KR, Husain S. Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J Heart Lung Transplant. 2008;27(8):850–5. https://doi.org/10.1016/j.healun.2008.05.021.CrossRefPubMed

35.

Thomson S, Alibhai K, Winkelaar G, Lien D, Halloran K, Kapasi A, et al. Case report of vertebral osteomyelitis and mycotic abdominal aortic aneurysm caused by Scedosporium apiospermum in a lung transplant patient with cystic fibrosis. Transplant Proc. 2015;47(1):204–9. https://doi.org/10.1016/j.transproceed.2014.07.072.CrossRefPubMed

36.

Peghin M, Monforte V, Martin-Gomez MT, Ruiz-Camps I, Berastegui C, Saez B, et al. Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients. Transpl Infect Dis. 2016;18(1):70–8. https://doi.org/10.1111/tid.12492.CrossRefPubMed

37.

Kim SH, Ha YE, Youn JC, Park JS, Sung H, Kim MN, et al. Fatal scedosporiosis in multiple solid organ allografts transmitted from a nearly-drowned donor. Am J Transplant. 2015;15(3):833–40. https://doi.org/10.1111/ajt.13008.CrossRefPubMed

38.

Baker AW, Maziarz EK, Arnold CJ, Johnson MD, Workman AD, Reynolds JM, et al. Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis. Clin Infect Dis. 2020;70(1):30–9. https://doi.org/10.1093/cid/ciz156.CrossRefPubMed

39.••

Seidel D, Meissner A, Lackner M, Piepenbrock E, Salmanton-Garcia J, Stecher M, et al. Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope((R)). Crit Rev Microbiol. 2019;45(1):1–21. https://doi.org/10.1080/1040841X.2018.1514366A recent review summarising the epidemiology, prognostic factors, antifungal susceptibility and management of invasive scedosporiosis and lomentosporiosis in adults.CrossRefPubMed

40.

Castiglioni B, Sutton DA, Rinaldi MG, Fung J, Kusne S. Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore). 2002;81(5):333–48. https://doi.org/10.1097/00005792-200209000-00001.CrossRefPubMed

41.

Sheu R, Bricker AO, Sahi H, Mohammed TL. Pseudallescheria boydii (Scedosporium species) in 3 lung transplant recipients: computed tomography findings and literature review. J Comput Assist Tomogr. 2009;33(2):247–52. https://doi.org/10.1097/RCT.0b013e318172d629.CrossRefPubMed

42.

Mitomo H, Sakurada A, Matsuda Y, Notsuda H, Watanabe T, Oishi H, et al. Endobronchial topical Amphotericin B instillation for pulmonary chromomycosis after lung transplantation: a case report. Transplant Proc. 2018;50(3):939–42. https://doi.org/10.1016/j.transproceed.2017.12.028.CrossRefPubMed

43.

Sahi H, Avery RK, Minai OA, Hall G, Mehta AC, Raina P, et al. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant. 2007;26(4):350–6. https://doi.org/10.1016/j.healun.2007.01.011.CrossRefPubMed

44.

Rabodonirina M, Paulus S, Thevenet F, Loire R, Gueho E, Bastien O, et al. Disseminated Scedosporium prolificans (S. inflatum) infection after single-lung transplantation. Clin Infect Dis. 1994;19(1):138–42. https://doi.org/10.1093/clinids/19.1.138.CrossRefPubMed

45.

Abela IA, Murer C, Schuurmans MM, Schmitt JW, Muller F, Imkamp F, et al. A cluster of scedosporiosis in lung transplant candidates and recipients: The Zurich experience and review of the literature. Transpl Infect Dis. 2018;20(1):e12792. https://doi.org/10.1111/tid.12792.

46.

Musk M, Chambers D, Chin W, Murray R, Gabbay E. Successful treatment of disseminated scedosporium infection in 2 lung transplant recipients: review of the literature and recommendations for management. J Heart Lung Transplant. 2006;25(10):1268–72. https://doi.org/10.1016/j.healun.2006.06.002.CrossRefPubMed

47.

Denton EJ, Smibert O, Gooi J, Morrissey CO, Snell G, McGiffin D, et al. Invasive Scedosporium sternal osteomyelitis following lung transplant: Cured. Med Mycol Case Rep. 2016;12:14–6. https://doi.org/10.1016/j.mmcr.2016.07.001.CrossRefPubMedPubMedCentral

48.

Sayah DM, Schwartz BS, Kukreja J, Singer JP, Golden JA, Leard LE. Scedosporium prolificans pericarditis and mycotic aortic aneurysm in a lung transplant recipient receiving voriconazole prophylaxis. Transpl Infect Dis. 2013;15(2):E70–4. https://doi.org/10.1111/tid.12056.CrossRefPubMed

49.

Kelly M, Stevens R, Konecny P. Lomentospora prolificans endocarditis--case report and literature review. BMC Infect Dis. 2016;16:36. https://doi.org/10.1186/s12879-016-1372-y.CrossRefPubMedPubMedCentral

50.

Hot A, Maunoury C, Poiree S, Lanternier F, Viard JP, Loulergue P, et al. Diagnostic contribution of positron emission tomography with [18F]fluorodeoxyglucose for invasive fungal infections. Clin Microbiol Infect. 2011;17(3):409–17. https://doi.org/10.1111/j.1469-0691.2010.03301.x.CrossRefPubMed

51.

Blasco-Lucas A, Reyes-Juárez JL, Nazarena Pizzi M, Permanyer E, Evangelista A, Galiñanes M. Aortic Arch Mycotic Aneurysm Due to Scedosporium Apiospermum Reconstructed With Homografts. Ann Thorac Surg. 2015;99(6):2218–20. https://doi.org/10.1016/j.athoracsur.2014.08.067.CrossRefPubMed

52.

Husain S, Muñoz P, Forrest G, Alexander BD, Somani J, Brennan K, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40(1):89–99. https://doi.org/10.1086/426445.CrossRefPubMed

53.

Morio F, Horeau-Langlard D, Gay-Andrieu F, Talarmin JP, Haloun A, Treilhaud M, et al. Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J Clin Microbiol. 2010;48(5):1978–82. https://doi.org/10.1128/JCM.01840-09.CrossRefPubMedPubMedCentral

54.

Campa-Thompson MM, West JA, Guileyardo JM, Spak CW, Sloan LM, Beal SG. Clinical and morphologic findings in disseminated Scedosporium apiospermum infections in immunocompromised patients. Proc (Bayl Univ Med Cent). 2014;27(3):253–6. https://doi.org/10.1080/08998280.2014.11929129.CrossRefPubMedPubMedCentral

55.

Cortez KJ, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008;21(1):157–97. https://doi.org/10.1128/CMR.00039-07.CrossRefPubMedPubMedCentral

56.

Coron N, Pihet M, Fréalle E, Lemeille Y, Pinel C, Pelloux H, et al. Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study. Mycopathologia. 2018;183(1):101–17. https://doi.org/10.1007/s11046-017-0173-1.CrossRefPubMed

57.

Horré R, Marklein G. Isolation and clinical significance of Pseudallescheria and Scedosporium species. Med Mycol. 2009;47(4):415–21. https://doi.org/10.1080/13693780902801259.CrossRefPubMed

58.

Pham T, Giraud S, Schuliar G, Rougeron A, Bouchara J-P. Scedo-Select III: a new semi-selective culture medium for detection of the Scedosporium apiospermum species complex. Med Mycol. 2015;53(5):512–9. https://doi.org/10.1093/mmy/myv015.CrossRefPubMed

59.

Hedayati MT, Tavakoli M, Maleki M, Heidari S, Mortezaee V, Gheisari M, et al. Fungal epidemiology in cystic fibrosis patients with a special focus on Scedosporium species complex. Microb Pathog. 2019;129:168–75. https://doi.org/10.1016/j.micpath.2019.02.009.CrossRefPubMed

60.

Hong G, Miller HB, Allgood S, Lee R, Lechtzin N, Zhang SX. Use of Selective Fungal Culture Media Increases Rates of Detection of Fungi in the Respiratory Tract of Cystic Fibrosis Patients. J Clin Microbiol. 2017;55(4):1122–30. https://doi.org/10.1128/JCM.02182-16.CrossRefPubMedPubMedCentral

61.

Borman AM, Palmer MD, Delhaes L, Carrère J, Favennec L, Ranque S, et al. Lack of standardization in the procedures for mycological examination of sputum samples from CF patients: a possible cause for variations in the prevalence of filamentous fungi. Med Mycol. 2010;48(Suppl 1):S88–97. https://doi.org/10.3109/13693786.2010.511287.CrossRefPubMed

62.

Levesque E, Rizk F, Noorah Z, Aït-Ammar N, Cordonnier-Jourdin C, El Anbassi S, et al. Detection of (1,3)-β-d-Glucan for the diagnosis of invasive fungal infection in liver transplant recipients. Int J Mol Sci. 2017;18(4):862. https://doi.org/10.3390/ijms18040862.

63.

Ochi Y, Hiramoto N, Takegawa H, Yonetani N, Doi A, Ichikawa C, et al. Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy. Int J Hematol. 2015;101(6):620–5. https://doi.org/10.1007/s12185-015-1752-x.CrossRefPubMed

64.

Cuétara MS, Alhambra A, Moragues MD, González-Elorza E, Pontón J, del Palacio A. Detection of (1-->3)-beta-D-glucan as an adjunct to diagnosis in a mixed population with uncommon proven invasive fungal diseases or with an unusual clinical presentation. Clin Vaccine Immunol. 2009;16(3):423–6. https://doi.org/10.1128/CVI.00009-09.CrossRefPubMedPubMedCentral

65.••

Chen SCA, Halliday CL, Hoenigl M, Cornely OA, Meyer W. Scedosporium and Lomentospora infections: contemporary microbiological tools for the diagnosis of invasive disease. J Fungi (Basel). 2021;7(1):23. https://doi.org/10.3390/jof7010023A recent review summarising microbiological tools for the detection and diagnosis of invasive scedosporiosis and lomentosporiosis.

66.

Zeller I, Schabereiter-Gurtner C, Mihalits V, Selitsch B, Barousch W, Hirschl AM, et al. Detection of fungal pathogens by a new broad range real-time PCR assay targeting the fungal ITS2 region. Journal of Medical Microbiology. 2017;66(10):1383–92. https://doi.org/10.1099/jmm.0.000575.CrossRefPubMed

67.

Gomez CA, Budvytiene I, Zemek AJ, Banaei N. Performance of targeted fungal sequencing for culture-independent diagnosis of invasive fungal disease. Clin Infect Dis. 2017;65(12):2035–41. https://doi.org/10.1093/cid/cix728.CrossRefPubMed

68.

McTaggart LR, Copeland JK, Surendra A, Wang PW, Husain S, Coburn B, et al. Mycobiome sequencing and analysis applied to fungal community profiling of the lower respiratory tract during fungal pathogenesis. Front Microbiol. 2019;10:512. https://doi.org/10.3389/fmicb.2019.00512.CrossRefPubMedPubMedCentral

69.

Vagefi MR, Kim ET, Alvarado RG, Duncan JL, Howes EL, Crawford JB. Bilateral endogenous Scedosporium prolificans endophthalmitis after lung transplantation. Am J Ophthalmol. 2005;139(2):370–3. https://doi.org/10.1016/j.ajo.2004.08.005.CrossRefPubMed

70.

Balandin B, Aguilar M, Sanchez I, Monzon A, Rivera I, Salas C, et al. Scedosporium apiospermum and S. prolificans mixed disseminated infection in a lung transplant recipient: An unusual case of long-term survival with combined systemic and local antifungal therapy in intensive care unit. Med Mycol Case Rep. 2016;11:53–6. https://doi.org/10.1016/j.mmcr.2016.04.006.CrossRefPubMedPubMedCentral

71.

Ference EH, Kubak BM, Zhang P, Suh JD. Successful Treatment of Scedosporium Sinusitis in Two Lung Transplant Recipients: Review of the Literature and Recommendations for Management. Allergy Rhinol (Providence). 2019;10:2152656719827253. https://doi.org/10.1177/2152656719827253.CrossRef

72.

Cobo F, Lara-Oya A, Rodriguez-Granger J, Sampedro A, Aliaga-Martinez L, Navarro-Mari JM. Infections caused by Scedosporium/Lomentospora species: clinical and microbiological findings in 21 cases. Med Mycol. 2018;56(8):917–25. https://doi.org/10.1093/mmy/myx147.CrossRefPubMed

73.

Jenks JD, Reed SL, Seidel D, Koehler P, Cornely OA, Mehta SR, et al. Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents. 2018;52(5):706–12. https://doi.org/10.1016/j.ijantimicag.2018.08.005.CrossRefPubMedPubMedCentral

74.

Paajanen J, Halme M, Palomaki M, Anttila VJ. Disseminated Scedosporium apiospermum central nervous system infection after lung transplantation: a case report with successful recovery. Med Mycol Case Rep. 2019;24:37–40. https://doi.org/10.1016/j.mmcr.2019.03.003.CrossRefPubMedPubMedCentral

75.

Miraldi F, Anile M, Ruberto F, Tritapepe L, Puglese F, Quattrucci S, et al. Scedosporium apiospermum atrial mycetomas after lung transplantation for cystic fibrosis. Transpl Infect Dis. 2012;14(2):188–91. https://doi.org/10.1111/j.1399-3062.2011.00679.x.CrossRefPubMed

76.

Hirschi S, Letscher-Bru V, Pottecher J, Lannes B, Jeung MY, Degot T, et al. Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient. J Clin Microbiol. 2012;50(12):4168–70. https://doi.org/10.1128/JCM.01928-12.CrossRefPubMedPubMedCentral

77.

Tarabishy AB, Khatib OF, Nocero JR, Budev M, Kaiser PK. Ocular complications in patients with lung transplants. Br J Ophthalmol. 2011;95(9):1295–8. https://doi.org/10.1136/bjo.2010.191585.CrossRefPubMed

78.

Symoens F, Knoop C, Schrooyen M, Denis O, Estenne M, Nolard N, et al. Disseminated Scedosporium apiospermum infection in a cystic fibrosis patient after double-lung transplantation. J Heart Lung Transplant. 2006;25(5):603–7. https://doi.org/10.1016/j.healun.2005.12.011.CrossRefPubMed

79.

Raj R, Frost AE. Scedosporium apiospermum fungemia in a lung transplant recipient. Chest. 2002;121(5):1714–6. https://doi.org/10.1378/chest.121.5.1714.CrossRefPubMed

80.

Luijk B, Ekkelenkamp MB, De Jong PA, Kwakkel-van Erp JM, Grutters JC, van Kessel DA, et al. Effective prolonged therapy with Voriconazole in a lung transplant recipient with Spondylodiscitis induced by Scedosporium apiospermum. Case Rep Infect Dis. 2011;2011:460313–4. https://doi.org/10.1155/2011/460313.CrossRefPubMedPubMedCentral

81.

Sole A, Garcia-Robles AA, Jorda C, Cases Viedma E, Mancheno N, Poveda-Andres JL, et al. Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection. Am J Transplant. 2018;18(2):504–9. https://doi.org/10.1111/ajt.14580.CrossRefPubMed

82.

Rolfe NE, Haddad TJ, Wills TS. Management of Scedosporium apiospermum in a pre- and post-lung transplant patient with cystic fibrosis. Med Mycol Case Rep. 2013;2:37–9. https://doi.org/10.1016/j.mmcr.2013.01.002.CrossRefPubMedPubMedCentral

83.

Scott M, Wanat K, Pappas-Taffer L. Sporotrichoid eruption in a patient after lung transplantation. Scedosporium apiospermum fungal thrombophlebitis and sporotrichoid nodules. JAMA Dermatol. 2014;150(1):83–4. https://doi.org/10.1001/jamadermatol.2013.5382.CrossRefPubMed

84.

Lackner M, de Hoog GS, Verweij PE, Najafzadeh MJ, Curfs-Breuker I, Klaassen CH, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother. 2012;56(5):2635–42. https://doi.org/10.1128/AAC.05910-11.CrossRefPubMedPubMedCentral

85.•

Hoenigl M, Salamanton-García J, Walsh TJ, Nucci M, Neoh CF, Jenks JD et al. Global guideline for the diagnosis and management of rare mold infections: an initiative of the ECMM in cooperation with ISHAM and ASM. Lancet Infect Dis. 2021; https://doi.org/10.1016/S1473-3099(20)30784-2. A recent global guideline summarises the evidence and recommendations for diagnosis and treatment of rare mould infections including scedosporiosis and lomentosporiosis.

86.•

Jenks JD, Seidel D, Cornely OA, Chen S, van Hal S, Kauffman C, et al. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope(R) registry 2008-2019. Clin Microbiol Infect. 2020;26(6):784 e1- e5. https://doi.org/10.1016/j.cmi.2020.01.012A study revealed that combination therapy with voriconazole and terbinafine may be associated with improved clinical outcomes in patients with invasive Lomentospora prolificans infections.CrossRef

87.•

Jenks JD, Seidel D, Cornely OA, Chen S, van Hal S, Kauffman C, et al. Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope((R)) registry. Mycoses. 2020;63(5):437–42. https://doi.org/10.1111/myc.13067A study describing the clinical characteristics and treatment outcomes of patients with invasive scedosporiosis and lomentosporiosis.CrossRefPubMed

88.••

Seidel D, Hassler A, Salmanton-Garcia J, Koehler P, Mellinghoff SC, Carlesse F, et al. Invasive Scedosporium spp. and Lomentospora prolificans infections in pediatric patients: Analysis of 55 cases from FungiScope(R) and the literature. Int J Infect Dis. 2020;92:114–22. https://doi.org/10.1016/j.ijid.2019.12.017A recent review summarising the risk groups, clinical manifestation and management of invasive scedosporiosis and lomentosporiosis in paediatrics.CrossRefPubMed

89.

Caston JJ, Linares MJ, Rivero A, Casal M, Torre-Cisneros J. Clinical differences between invasive pulmonary infection by Scedosporium apiospermum and invasive pulmonary aspergillosis. Mycoses. 2011;54(5):e468–73. https://doi.org/10.1111/j.1439-0507.2010.01952.x.CrossRefPubMed

90.•

Vazirani J, Westall GP, Snell GI, Morrissey CO. Scedosporium apiospermum and Lomentospora prolificans in lung transplant patients - A single center experience over 24 years. Transpl Infect Dis. 2020:e13546. https://doi.org/10.1111/tid.13546A recent study describing the outcomes of lung transplant recipients with Scedosporium apiospermum and Lomentospora prolificans colonisation and infections.

91.

Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, et al. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. Transpl Infect Dis. 2009;11(3):211–9. https://doi.org/10.1111/j.1399-3062.2009.00384.x.CrossRefPubMed

92.

Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76. https://doi.org/10.1093/cid/ciz1008.CrossRefPubMed

93.

Husain S, Mooney ML, Danziger-Isakov L, Mattner F, Singh N, Avery R, et al. A 2010 working formulation for the standardization of definitions of infections in cardiothoracic transplant recipients. J Heart Lung Transplant. 2011;30(4):361–74. https://doi.org/10.1016/j.healun.2011.01.701.CrossRefPubMedPubMedCentral

Title: Scedosporium and Lomentospora infections in lung transplant recipients
Authors: Blandine Rammaert
Zoe C. F. Neoh
Sharon C-A. Chen
David C. M. Kong
Monica A. Slavin
Publication date: 01-09-2021
Publisher: Springer US
Keywords: Voriconazole
Cystic Fibrosis
Cystic Fibrosis
Published in: Current Fungal Infection Reports / Issue 3/2021
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-021-00416-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2021

Candida auris: Diagnostic Challenges and Emerging Opportunities for the Clinical Microbiology Laboratory

Molecular Diagnosis of Yeast Infections

Investigational Agents for the Treatment of Resistant Yeasts and Molds

Emergence of Triazole Resistance in Aspergillus spp. in Latin America

Cytopathology of Fungal Infections

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage